ANI Pharmaceuticals (ANIP) News Today $66.33 +0.35 (+0.53%) Closing price 04:00 PM EasternExtended Trading$68.66 +2.33 (+3.51%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Intech Investment Management LLC Has $983,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Intech Investment Management LLC raised its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 41.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,780 shares of the specialty pharmaceutical compMarch 23 at 4:12 AM | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by AlphaQuest LLCAlphaQuest LLC decreased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 94.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 516 shares of the specialty pharmaceutical company's stock after selling 9,377 shares dMarch 22 at 3:28 AM | marketbeat.comCharles Schwab Investment Management Inc. Trims Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Charles Schwab Investment Management Inc. reduced its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 5.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 236,157 shares of the specialty phaMarch 22 at 3:10 AM | marketbeat.comANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the Launch of Nitazoxanide TabletsMarch 19, 2025 | finanznachrichten.deANI Pharmaceuticals launches Nitazoxanide Tablets, 500 mg.March 19, 2025 | markets.businessinsider.comANI Pharmaceuticals Announces the Launch of Nitazoxanide TabletsMarch 19, 2025 | globenewswire.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Increased by William Blair Investment Management LLCWilliam Blair Investment Management LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48March 19, 2025 | marketbeat.comANI Pharmaceuticals announces royalty obligation buyout for Iluvien, YutiqMarch 19, 2025 | markets.businessinsider.comANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN and YUTIQMarch 18, 2025 | finanznachrichten.deANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®March 18, 2025 | finance.yahoo.comANI Pharmaceuticals' (ANIP) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday.March 18, 2025 | marketbeat.comANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®March 18, 2025 | globenewswire.comANI Pharmaceuticals (NASDAQ:ANIP) Upgraded by StockNews.com to "Hold" RatingMarch 17, 2025 | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated at Jefferies Financial GroupMarch 16, 2025 | americanbankingnews.comBank of New York Mellon Corp Increases Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Bank of New York Mellon Corp lifted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 123,832 shares of the speciaMarch 16, 2025 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Upgraded at StockNews.comStockNews.com raised shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday.March 15, 2025 | marketbeat.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of StockANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the transaction, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.March 15, 2025 | marketbeat.comJefferies Initiates Coverage of ANI Pharmaceuticals (ANIP) with Buy RecommendationMarch 15, 2025 | msn.comANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Jefferies Financial GroupJefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research note on Friday. They issued a "buy" rating and a $80.00 price objective on the stock.March 15, 2025 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 400 SharesMarch 15, 2025 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.March 15, 2025 | americanbankingnews.comAnalysts Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $79.00March 15, 2025 | americanbankingnews.comANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN LabelMarch 14, 2025 | finanznachrichten.deANI Pharmaceuticals initiated with a Buy at JefferiesMarch 14, 2025 | markets.businessinsider.comANI Pharmaceuticals announces FDA approval for expansion of Iluvien labelMarch 14, 2025 | markets.businessinsider.comThompson Siegel & Walmsley LLC Increases Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Thompson Siegel & Walmsley LLC grew its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 23.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 283,860 shares of the specialty pharmaceutical company's stock afterMarch 14, 2025 | marketbeat.comANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® LabelMarch 14, 2025 | globenewswire.comJP Morgan Initiates Coverage of ANI Pharmaceuticals (ANIP) with Overweight RecommendationMarch 13, 2025 | msn.comANI Pharmaceuticals initiated with an Overweight at JPMorganMarch 12, 2025 | markets.businessinsider.comANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at JPMorgan Chase & Co.JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday. They set an "overweight" rating and a $85.00 price target for the company.March 12, 2025 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of "Buy" by AnalystsShares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, six have assigned a buy ratiMarch 12, 2025 | marketbeat.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells 1,000 Shares of StockANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the sale, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This represents a 1.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.March 11, 2025 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis Sells 1,000 SharesMarch 11, 2025 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by Global Alpha Capital Management Ltd.Global Alpha Capital Management Ltd. grew its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 16.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 624,550 shares of the specialty pharmaceutical company's stock aMarch 9, 2025 | marketbeat.comLisanti Capital Growth LLC Grows Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Lisanti Capital Growth LLC grew its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 80.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,910 shares of the specialMarch 8, 2025 | marketbeat.comEquities Analysts Offer Predictions for ANIP Q1 EarningsANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for ANI Pharmaceuticals in a research report issued on Monday, March 3rd. HC Wainwright analyst O. Livnat expects that the specialty pharmaceutical company will postMarch 7, 2025 | marketbeat.comGuggenheim Forecasts Strong Price Appreciation for ANI Pharmaceuticals (NASDAQ:ANIP) StockGuggenheim boosted their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a "buy" rating in a research report on Wednesday.March 6, 2025 | marketbeat.comANI Pharmaceuticals Receives FDA Approval for Purified Cortrophin® Gel Prefilled Syringe FormatMarch 5, 2025 | nasdaq.comGeneric Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs PeersMarch 5, 2025 | finance.yahoo.comANI Pharmaceuticals price target raised to $86 from $84 at GuggenheimMarch 5, 2025 | markets.businessinsider.comANI Pharmaceuticals (NASDAQ:ANIP) Downgraded to "Sell" Rating by StockNews.comStockNews.com lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday.March 4, 2025 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2025 Earnings GuidanceANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2025 earnings guidance. The company provided EPS guidance of 6.120-6.490 for the period, compared to the consensus estimate of 5.560. The company also issued revenue guidance of $756.0 millionillion-$776.0 millionillion, compared to the consensus estimate of $724.9 millionillion.March 4, 2025 | marketbeat.comANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled SyringeMarch 3, 2025 | globenewswire.comTruist Financial Sticks to Their Hold Rating for ANI Pharmaceuticals (ANIP)March 3, 2025 | markets.businessinsider.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call TranscriptMarch 3, 2025 | insidermonkey.comHC Wainwright Reiterates "Buy" Rating for ANI Pharmaceuticals (NASDAQ:ANIP)HC Wainwright reaffirmed a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday.March 3, 2025 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Issues Quarterly Earnings ResultsANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) posted its quarterly earnings data on Friday. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.22. The company had revenue of $190.60 million during the quarter, compared to analyst estimates of $175.36 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm's quarterly revenue was up 44.8% on a year-over-year basis. During the same quarter last year, the company earned $0.04 earnings per share.March 1, 2025 | marketbeat.comANI Pharmaceuticals reports Q4 adjusted EPS $1.63 vs. $1.00 last yearMarch 1, 2025 | markets.businessinsider.comANI Pharmaceuticals sees FY25 adjusted EPS $6.12-$6.49March 1, 2025 | markets.businessinsider.comWhy Is ANI Pharmaceuticals (ANIP) Stock Soaring TodayMarch 1, 2025 | msn.com Remove Ads Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIP Media Mentions By Week ANIP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIP News Sentiment▼0.680.68▲Average Medical News Sentiment ANIP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIP Articles This Week▼85▲ANIP Articles Average Week Remove Ads Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Krystal Biotech News Nuvalent News Cytokinetics News Verona Pharma News Grifols News Elanco Animal Health News ADMA Biologics News PTC Therapeutics News Avidity Biosciences News Arcellx News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIP) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
